Free tool
FAERS Monitor: Miplyffa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214927 or its brand name (Miplyffa, Arimoclomol Citrate). Reports on generic versions are filed under their own applications.
Reports
46
Serious
16
35% of reports
Hospitalization
10
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea6
- vomiting5
- product size issue4
- insomnia3
- pneumonia aspiration3
- death2
- fall2
- fatigue2
- gait disturbance2
- pneumonia2
- product administration interrupted2
- product distribution issue2
- product use complaint2
- seizure2
- sepsis2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2025 | 39 |
| 2026 | 6 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,113 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product size issueSignal | 4 | 340.5 | 133.5 | 1,035 |
| product administration interrupted | 2 | 116.5 | 30.0 | 128 |
| product distribution issue | 2 | 98.6 | 25.4 | 108 |
| product use complaint | 2 | 58.1 | 15.0 | 62 |
| pneumonia aspirationSignal | 3 | 54.9 | 18.4 | 110 |
| sepsis | 2 | 8.2 | 2.1 | 7 |
| seizure | 2 | 7.9 | 2.0 | 6 |
| insomniaSignal | 3 | 5.2 | 1.7 | 6 |
| vomitingSignal | 5 | 4.9 | 2.1 | 12 |
| gait disturbance | 2 | 4.8 | 1.2 | 3 |
| diarrhoeaSignal | 6 | 4.3 | 2.0 | 12 |
| pneumonia | 2 | 2.8 | 0.7 | 1 |
| fall | 2 | 2.7 | 0.7 | 1 |
| fatigue | 2 | 1.2 | 0.3 | 0 |
| death | 2 | 1.1 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.